Plus: Groupon cofounder’s healthcare venture, investments in CAR-T therapies and the upcoming Forbes Healthcare Summit.

AbbVie should report strong Q3 2024 results next week and increase the full-year guidance. Explore more details here.

The U.S. Food and Drug Administration has approved AbbVie's Vyalev (foscarbidopa and foslevodopa) for adults living with ...

Neurologist Jason Aldred helped conduct trials for the device in Spokane through his work at Selkirk Neurology, where he ...

The U.S. Food and Drug Administration has approved Vyalev (foscarbidopa and foslevodopa) for adults living with advanced ...

Valuation metrics show AbbVie to be only slightly undervalued based on FY 2025 projections. Read why I'm neutral on ABBV ...

Knowledge on the genetic basis of Parkinson's disease has grown tremendously since the discovery of the first monogenic form, ...

The US Food and Drug Administration has approved VYALEV, a groundbreaking therapy developed by AbbVie to treat adults with ...

The U.S. FDA has approved the first 24-hour continuous subcutaneous infusion for adults with advanced Parkinson’s disease.

North Chicago, Illinois Saturday, October 19, 2024, 12:00 Hrs [IST] ...

Here's a recap of the week’s most important stories.

The FDA has just approved a new injectable treatment for adults with advanced Parkinson’s disease called Vyalev (also known as Produodopa).